Virtus LifeSci Biotech Products ETF (BBP) Declines 0.71% for May 17

May 17 is a negative day so far for Virtus LifeSci Biotech Products ETF (NASDAQ:BBP) as the ETF is active during the day after losing 0.71% to hit $39.78 per share. The exchange traded fund has 35.61 million net assets and 1.69% volatility this month.

Over the course of the day 3,713 shares traded hands, as compared to an average volume of 7,670 over the last 30 days for Virtus LifeSci Biotech Products ETF (NASDAQ:BBP).

The ETF is -14.83% of its 52-Week High and 28.49% of its low, and is currently having ATR of 0.87. This year’s performance is 14.21% while this quarter’s performance is -3.20%.

The ETF’s YTD performance is 19.9%, the 1 year is 2.06% and the 3 year is 17.47%.

The ETF’s average P/E ratio is 15.12, the price to book is 3.6, the price to sales is 2.64 and the price to cashflow is 6.93. It was started on 12/17/2014. The fund’s top holdings are: Portola Pharmaceuticals Inc for 4.27% of assets, The Medicines Co for 3.74%, Array BioPharma Inc for 3.30%, Omeros Corp for 3.25%, Ultragenyx Pharmaceutical Inc for 3.22%, Ionis Pharmaceuticals Inc for 3.21%, Puma Biotechnology Inc for 3.20%, Radius Health Inc for 3.19%, Celgene Corp for 3.14%, ACADIA Pharmaceuticals Inc for 3.10%. The ETF sector weights are: Basic Materials 0.00%, CONSUMER_CYCLICAL 0.00%, Financial Services 0.00%, Realestate 0.00%, Consumer Defensive 0.00%, Healthcare 100.00%, Utilities 0.00%, Communication Services 0.00%, Energy 0.00%, Industrials 0.00%, Technology 0.00%. The ETF currently as yield.

More notable recent Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP) news were published by: which released: “Technical Tuesday: IWM’s Size Does Matter – Seeking Alpha” on January 29, 2019, also with their article: “SBIO: A Safe Play In Biotechnology? – Seeking Alpha” published on June 09, 2015, published: “Try This ETF Pair To Round Out Your Biotech Exposure – Seeking Alpha” on March 15, 2018. More interesting news about Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP) were released by: and their article: “Best And Worst Q2 2018: Healthcare ETFs And Mutual Funds – Seeking Alpha” published on May 11, 2018 as well as‘s news article titled: “Biotech Is Worth The Hype, But Do You Have The Data? – Seeking Alpha” with publication date: March 02, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.